Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients
Cardiovascular DiseaseCoronary Artery Occlusion1 moreThe NAGOMI COMPLEX PMCF (Post-Market Clinical Follow-up) study has been designed to expand the knowledge about outcomes with the Ultimaster Nagomi™ sirolimus eluting coronary stent system (Ultimaster Nagomi™) in complex PCI subjects. The features for a complex PCI are based upon subgroup analysis of earlier published studies.
NAVISCORE PMCF Study ( rEPIC04F )
Coronary Artery DiseaseIschemic Heart DiseaseMulticenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Naviscore scoring balloon to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Naviscore.
4D CT Scan Versus 3D CT Scan Concerning Cardiac Dosimetry Assesment for Left Sided Breast Cancers...
Breast CancerRadiation-Induced Vascular Disease5 moreTo establish if the cardiac radiation dose assesment is well aproximated with routine 3D CT scan compared to 4D CT experimental scan with respiratory gating (breath motion monitoring). The study population relates to left side breast cancers female patients that require a radiation therapy treatment.
Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort...
Coronary Artery DiseaseCoronary Artery Stenosis5 moreThis is a self-controlled cohort study to evaluate the efficacy and safety of comprehensive treatment in patients with inflammation-associated rapidly-progressive coronary artery disease (IR-CAD) by comparing the study endpoints before treatment with those after treatment in the same group of patients.
COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease
Heart FailureThe goal of this 2x2 factorial clinical trial is to test the efficacy of i) colchicine, and ii) thiamine in heart failure (HF) secondary to ischemic heart disease. The main questions it aims to answer are: Does colchicine reduce the risk of cardiovascular (CV) death, a HF event, or an ischemic CV event Does thiamine reduce the risk of cardiovascular (CV) death, or a HF event Participants will undergo the following procedures: Run-in: All participants will receive colchicine 0.5 mg daily to assess drug tolerance over a 3-4 week period. Randomization: If colchicine is tolerated during run-in, eligible participants will be randomized in a 2x2 factorial design to receive i) colchicine 0.5mg daily or placebo, and ii) thiamine 300mg daily or no thiamine. Follow-up: Clinical outcomes, side effects, adverse events, and drug adherence will be captured during follow-up
Group-based Cardiac Telerehabilitation and Its Effectiveness
Coronary Artery DiseaseCardiovascular diseases (CVD) and coronary artery diseases (CAD) are the most common cause of death worldwide. After an acute cardiac event, prevention of new cardiac events is essential and reduces suffering. Group-based cardiac telerehabilitation (CTR) refers to the use of information and communication technologies for rehabilitation purposes in promoting CAD patients´ health.
Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome
Heart FailureKidney Diseases4 moreTo estimate the characteristics, pathogenesis, risk factors and intervention measures for different stages of heart and kidney diseases, and to optimize the curative effects of different treatment schemes
STabilization of Atheroma By Lipid-reducing Effect of Drug-Coated Balloon (STABLE-DCB)
Coronary Artery DiseaseAtherosclerotic Plaque1 moreThis study aims to investigate whether DCB angioplasty, compared to statin-based medical treatment alone, will lead to more reduction in plaque lipid burden as assessed by near infrared spectroscopy (NIRS) at 6-9 months following the index procedure.
XIENCE Skypoint Large Vessel Post Approval Study
Coronary Artery DiseaseSPIRIT XLV PAS is a prospective, single arm, multi-center, US and OUS post-approval observational study to evaluate the continued safety and effectiveness of the XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS) Large Vessel (LV) sizes (diameter 4.5 mm and 5.0 mm) during commercial use in a real-world setting.
Multicenter Registry of Coronary Flow-Derived Indexes (MulticenterFLOW)
Coronary Microvascular DiseaseCoronary Artery Disease1 moreMulticenterFlow is a prospective, multi-center, registry study. The aim of the study is twofold: To evaluate prognostic implications of coronary microvascular disease (CMD) in patients with ischemic heart disease (IHD) undergoing revascularization decision using fractional flow reserve (FFR) or other non-hyperemic pressure ratios in deferred population To evaluate the efficacy of intravascular imaging-guided optimization to enhance post-revascularization coronary circulatory function, compared with angiography-only guided revascularization in revascularized population.